Else, Tobias

Adrenocortical carcinoma

Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews

Adrenal and Paraganglionic TumorsNeuroendocrine Tumor Research Advances

Cited by 892

Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling

Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research

Adrenal and Paraganglionic TumorsBreast Cancer Treatment Studies

Cited by 401

Adrenocortical carcinoma is a Lynch syndrome-associated cancer

Raymond, V. M., Everett, J. N., Furtado, L. V., Gustafson, S. L., Jungbluth, C. R., Gruber, S. B., Hammer, G. D., Stoffel, E. M., Greenson, J. K., Giordano, T. J., et al. (2013) · Journal of Clinical Oncology

Genetic factors in colorectal cancerAdrenal and Paraganglionic Tumors

Cited by 208

Targeted disruption of β-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex

Kim, A. C., Reuter, A. L., Zubair, M., Else, T., Serecky, K., Bingham, N. C., Lavery, G. G., Parker, K. L., & Hammer, G. D. (2008) · Development

Wnt/β-catenin signaling in development and cancerDevelopmental Biology and Gene Regulation

Cited by 202

European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency

Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism

Adrenal Hormones and DisordersStress Responses and Cortisol

Cited by 172

Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma

Raymond, V. M., Else, T., Everett, J. N., Long, J. M., Gruber, S. B., & Hammer, G. D. (2013) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsBRCA gene mutations in cancer

Cited by 105

Profiles of 21-Carbon Steroids in 21-Hydroxylase Deficiency

Turcu, A. F., Rege, J., Chomic, R., Liu, J., Nishimoto, H. K., Else, T., Moraitis, A. G., Palapattu, G. S., Rainey, W. E., & Auchus, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism

Sexual Differentiation and DisordersAdrenal Hormones and Disorders

Cited by 77

Urogenital and caudal dysgenesis in adrenocortical dysplasia ( acd ) mice is caused by a splicing mutation in a novel telomeric regulator

Keegan, C. E., Hutz, J. E., Else, T., Adamska, M., Shah, S. P., Kent, A. E., Howes, J. M., Beamer, W. G., & Hammer, G. D. (2005) · Human Molecular Genetics

Developmental Biology and Gene RegulationCongenital limb and hand anomalies

Cited by 68

American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach

Kiseljak-Vassiliades, K., Bancos, I., Hamrahian, A., Habra, M. A., Vaidya, A., Levine, A. C., & Else, T. (2020) · Endocrine Practice

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 66

Genetic p53 Deficiency Partially Rescues the Adrenocortical Dysplasia Phenotype at the Expense of Increased Tumorigenesis

Else, T., Trovato, A., Kim, A. C., Wu, Y., Ferguson, D. O., Kuick, R. D., Lucas, P. C., & Hammer, G. D. (2009) · Cancer Cell

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 62

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Iversen, A. B., Cornell, J., et al. (2025) · The Lancet Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 50

Phase II Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2020) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 42

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 22